Table 1.

Nasal and sinonasal tumors

Studies	Study type	Study period (years)	n	Technique	PhT	PCT (%)	OF (%)	Morphology	Observation median (months)	Results	Toxicity
Resto et al. [39]	Retro	1991-2002	102	PSPT		4	100	Different	61	5-year: LC - 95, 82, and 87%; OS - 90, 53, and 49% in groups R0, R1, and biopsy	Not evaluated
Russo etal. [71]	Retro	1991-2008	54	PSPT	-	39	69	HNSCC	82	5-year: LRC - 73%; OS - 47%	Stage III — in 9; IV — in 6
Nakamura et al. [72]	Retro	1999-2012	42	PSPT	-	26	0	Esthesioneuroblastoma	69	5-year OS/PFS: 100/80% — group A; 86/65% — group B; 76/39% — group C	Stage lll-IV — in 6: visual loop — 4; liquorrhea — 1; cataract — 1
Takagi et al. [73]	Retro	2002-2012	40	PSPT		0	0	Adenocarcinoma	38	5-year: OS - 63%; PFS - 30%; LC - 76%	Stage lll-V — in 36 (26%): III — in 24 (osteonecroses); IV — in 9 (vision loss); V — in 3 (radiation ulcers)
Demizu etal. [41]	Retro	2003-2011	33	PSPT	-	0	0	Melanoma	18	2-year: LC-71%; OS-44%	Stage lll-IV — in 3: cataract, mucositis, and pain
Linton et al. [74]	Retro	2004-2012	26	PSPT		0	77	Adenocarcinoma	25	2-year: LC - 95%; OS - 93% (without previous radiation)	Late toxicity, stage III — in 2; IV — in 1; V — in 1 (after a repeated course)
Fuji et al. [42]	Retro	2006-2012	20	PSPT	-	0	0	Melanoma	35	3-year: OS - 68%; PFS - 60%	Stage IV — in 1 (visual loop)
Dagan et al. [75]	Retro	2007-2013	84	PSPT		75	74	Different	32	3-year: LC — 83%; no metastases — 72%; OS - 68%	Stage lll-V (24%): cerebral necrosis — in 1; osteonecrosis/soft tissue necrosis — in 7; 3 fatal cases
Zenda et al. [43]	Pro	2008-2012	32	PSPT	-	0	0	Melanoma	36	1-year: LC-76%; 3-year: OS - 46%; PFS - 36%	Stage >lll — none
McDonald et al. [40]	Retro	2010-2014	40	PSPT	+	75	—	Different	—	—	In IMRT, tubes and narcotics were more frequently used
Patel et al. [44]	Retro	1975-2013	286	PSPT/ C-ions	+	—	—	Different	38	OS >5 years in hadron therapy group (p=0.0038) and in higher observation median (p=0.037), the same as PFS (p=0.0003)